2027 NCODA Global Oncology & Haematology Congress
March 10, 2027 | 9:00 AM EST
A23 / P23
NCODA Oncology and Hematology Meeting Abstracts | Volume 2 | Supplement 1
Publication Date: April 7, 2026
Effect of bezuclastinib on the pathobiology of mastocytosis: changes in bone marrow mast cells, tryptase, and KIT p.D816V variant allele frequency from the pivotal SUMMIT trial
Organization / Company:
1Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA; 2ARUP Laboratories, Salt Lake City, UT, USA; 3Uniformed Services University & Walter Reed National Military Medical Center, Bethesda, MD, USA; 4Cogent Biosciences Inc., Waltham, MA, USA; 5Duke Cancer Institute, Durham, NC, USA
NCODA Oncol Hematol Meet Abstr. 2026;2(suppl 1):abstr 23.
Share
Background:
Systemic mastocytosis (SM) includes a spectrum of subtypes characterized by variable degrees of neoplastic mast cell (MC) infiltration of tissues. The gain-offunction KIT p.D816V mutation drives SM in ~95% of patients. Most patients have nonadvanced SM (NonAdvSM). Pathological and molecular markers of disease burden, including degree of bone marrow (BM) MC infiltration, serum tryptase (ST) elevation, and KIT p.D816V variant allele frequency (VAF) detection, determine NonAdvSM subtype, indicate disease severity, and correspond to progression and survival risk. Bezuclastinib is an oral, potent, and selective type 1 tyrosine kinase inhibitor with activity against KIT D816V.3 The SUMMIT trial evaluated bezuclastinib in NonAdvSM. Here, we describe bezuclastinib’s effects on ST, KIT p.D816V VAF, and BM MCs in SUMMIT Part 2.
Objectives:
- Explain the therapeutic hypothesis of bezuclastinib, an oral, potent, and selective type 1 tyrosine kinase inhibitor, in nonadvanced systemic mastocytosis.
- Evaluate the pathological and molecular biomarker data of bezuclastinib from the pivotal SUMMIT trial in patients with nonadvanced systemic mastocytosis and recognize how therapeutic targeting of the underlying disease mechanism may improve patient outcomes.
- Understand the relevance of correlating subjective and objective measures of disease burden with emerging targeted therapies such as bezuclastinib.
Methods:
SUMMIT evaluated bezuclastinib in NonAdvSM patients with inadequate symptom control despite best supportive care (BSC) medications. Patients were randomized 2:1 to 100mg every day (QD) bezuclastinib+BSC or placebo+ BSC. Primary endpoint was 24-week mean change from baseline in Mastocytosis Symptom Severity Daily Diary (MS2D2) total symptom score (TSS) (range 0–110). Key secondary endpoints included the proportion of patients with ≥50% reduction in ST, KIT p.D816V VAF, BM MC burden, MS2D2 TSS, and ≥30% TSS reduction. ST, KIT p.D816V VAF, and BM biopsy were obtained at baseline and week 24 to determine the effect of bezuclastinib vs placebo on pathologic measures of disease. MC aggregation, morphology, and immunophenotype were assessed. Immunohistochemical staining for CD117, tryptase, CD25, CD30, and CD34 were performed on BM sections.
Results:
179 patients enrolled in SUMMIT Part 2: n=119 bezuclastinib, n=60 placebo; median age (range) 51 (23- 78) years; 65.9% female; mean (range) baseline MS2D2 TSS 55.6 (13-105). Median (range) baseline blood KIT p.D816V VAF was 0.25% (0-34%); 77.7% of patients had detectable KIT p.D816V at baseline. Median (range) baseline BM MC burden was 10% (1-75%); 75% had MC aggregates at baseline. Median (range) baseline ST was 40 (6-692) ng/ mL; ST was ≥20 ng/mL in 82.1%. Reduction in ST by >50% was achieved in 87.4% of patients receiving bezuclastinib vs 0% receiving placebo after 24 weeks (p<0.0001).
Conclusions:
Substantial reductions of KIT p.D816V VAF, in some cases to undetectable levels, and normalization of ST and BM MC percentage/morphology may represent reversal of underlying SM pathogenesis. The effect of bezuclastinib on these markers and changes in BM MC characteristics will be presented. The impact of bezuclastinib on the World Health Organization (WHO) SM diagnostic criteria supports targeted KIT inhibition as a disease-modifying mechanism in NonAdvSM.
Funding: Cogent Biosciences.
Prior Presentations:
Presented at the American Society of Hematology (ASH) Annual Meeting 2025, December 6-9, Orlando, FL.
Send your feedback
Please do not include any personal information or details.
"*" indicates required fields
Was this page
helpful?
Send your feedback
Please do not include any personal information or details.
"*" indicates required fields